.jpg?format=webp&width=780)
Diabetes mellitus (DM) is the leading cause of chronic kidney disease. In addition, Albuminuria is associated with an increased risk of cardiovascular mortality. Sodium‐glucose cotransporter two inhibitors (SGLT2‐Is) and mineralocorticoid receptor antagonists (MRAs) protect against Albuminuria; however, their combined effects on Albuminuria are unclear. Therefore, the authors performed a network meta‐analysis to investigate the effects of SGLT2‐Is, MRAs, and their combination on Albuminuria in type 2 DM. The present study concluded that combination therapy with SGLT2‐Is and MRAs has been associated with lower Albuminuria in patients with type 2 DM compared to monotherapy with SGLT2‐Is or MRAs alone.
Like
Save
Share